OBIZUR

BIOLOGICAL3 trials

Sponsors

Baxalta now part of Shire, Takeda

Conditions

Acquired Hemophilia A

Unknown Phase

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

CompletedNCT02610127

Baxalta now part of ShireAcquired Hemophilia A

Start: 2015-12-30End: 2019-06-07Updated: 2021-08-05

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

CompletedNCT03199794

Baxalta now part of ShireAcquired Hemophilia A

Start: 2016-12-14End: 2021-07-30Updated: 2022-07-21

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

RecruitingNCT06550882

TakedaAcquired Hemophilia A

Start: 2025-07-22End: 2026-12-31Target: 9Updated: 2026-09-11

Related Papers

Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS.

2024-09-02

Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study

Haemophilia2023-08-162 citations